Product Description: Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Jonas S Heitmann, et al. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers (Basel). 2021 Feb 1;13(3):549.